All articles by Salong Debbarma

Salong Debbarma

R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia

R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in chronic kidney disease…
FDA issues CRL to Aldeyra’s reproxalap drug application

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics for its new…
FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis

The US Food and Drug Administration (FDA) has accepted for review Sun Pharmaceutical’s supplemental biologics licence application (sBLA) submitted for…
Sentynl and PRG partner for Progerinin licence

Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule…
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery

Biophytis has expanded its existing partnership with LynxKite Technologies to accelerate AI-driven longevity drug discovery, beginning with the MAS Receptor…

Novartis wins FDA approval for Cosentyx to treat paediatric HS patients

Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years…
PRISM BioLab partners with Receptor.AI for molecule discovery

PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available…
PsiQuantum and National Cancer Center Japan partner on quantum computing

PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing…
Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract…
Curatis and Neupharma sign development agreement for corticorelin in Japan

Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema…